Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

EVMN

Evommune Inc

May 29 • 03:50PM ET

22.94

-0.39 -1.67 %

Healthcare • Biotechnology • USA • Small • NYSE

Peers: KYMR NUVL RYTM INCY BMRN VKTX KRYS AXSM MDGL NBIX

| Held by: VTI IWM VXF VTWO SCHA IWO IWN IWC SCHB VTWG

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.39	Insider Own	46.57%	Shs Outstand	36.02M	Perf Week	-2.59%
Market Cap	826.26M	Forward P/E	-	EPS next Y	-2.77	Insider Trans	0.01%	Shs Float	19.24M	Perf Month	-3.82%
Enterprise Value	623.91M	PEG	-	EPS next Q	-0.66	Inst Own	59.85%	Short Float	16.11%	Perf Quarter	-11.77%
Income	-75.99M	P/S	82.63	EPS this Y	73.35%	Inst Trans	27.02%	Short Ratio	9.18	Perf Half Y	22.35%
Sales	10.00M	P/B	2.71	EPS next Y	7.48%	ROA	-40.15%	Short Interest	3.10M	Perf YTD	34.00%
Book/sh	8.46	P/C	3.91	EPS next 5Y	31.93%	ROE	-103.87%	52W High	33.20 -30.90%	Perf Year	-
Cash/sh	5.87	P/FCF	-	EPS past 3/5Y	-38.91% -	ROIC	-24.37%	52W Low	13.89 65.21%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	61.25% -	Gross Margin	86.39%	Volatility	6.39% 6.57%	Perf 5Y	-
Dividend TTM	-	EV/Sales	62.39	EPS Y/Y TTM	-	Oper. Margin	-899.92%	ATR (14)	1.50	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	20.36	Sales Y/Y TTM	-	Profit Margin	-759.87%	RSI (14)	46.52	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	20.36	EPS Q/Q	-33.00%	SMA20	-0.49%	Beta	-	Target Price	52.33
Payout	-	Debt/Eq	0.03	Sales Q/Q	-100.00%	SMA50	-5.25%	Rel Volume	0.42	Prev Close	23.33
Employees	48	LT Debt/Eq	0.02	Earnings	May 07 AMC	SMA200	3.66%	Avg Volume	337.69K	Price	22.94
IPO	Nov 06, 2025	Option/Short	Yes / Yes	EPS/Sales Surpr.	21.28% -100.00%	Trades		Volume	138,058	Change	-1.67%

Date	Action	Analyst	Rating Change	Price Target Change
May-01-26	Initiated	Stifel	Buy	$54
Apr-07-26	Resumed	Oppenheimer	Outperform	$50
Jan-22-26	Initiated	Oppenheimer	Outperform	$42
Jan-08-26	Initiated	Raymond James	Strong Buy	$40
Jan-06-26	Initiated	H.C. Wainwright	Buy	$35
Dec-01-25	Initiated	William Blair	Outperform
Dec-01-25	Initiated	Morgan Stanley	Overweight	$36
Dec-01-25	Initiated	Leerink Partners	Outperform	$42
Dec-01-25	Initiated	Evercore ISI	Outperform	$40
Dec-01-25	Initiated	Cantor Fitzgerald	Overweight

May-07-26 04:05PM	Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights (Business Wire) -5.58%
Apr-10-26 04:00AM	Biotechs IPO comeback; Trumps tariff loophole for pharma (Pharma Voice) -10.96%
Apr-07-26 04:00AM	Evommune bucked biotech IPO drought and is focused on the long game (Pharma Voice)
Apr-06-26 09:00AM	Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine (Business Wire)
Mar-23-26 08:15AM	Apogee strengthens case for longer-lasting eczema drug (BioPharma Dive)
01:16PM	Loading…
Mar-18-26 01:16PM	Evommune Stock Sees RS Rating Rise To 91 (Investor's Business Daily)
09:34AM	Block upgraded, Starbucks downgraded: Wall Street's top analyst calls (The Fly)
Mar-05-26 04:01PM	Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights (Business Wire) +6.36% +5.62%
Feb-25-26 10:27AM	Evommune CEO Luis Pena Reveals Whats Behind Companys Post-IPO Success (NYSE) +7.10%
Feb-15-26 09:59AM	Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet (Benzinga)
Feb-12-26 08:30PM	Evommune Announces $125 Million Private Placement (Business Wire) +13.24%
09:46AM	Evommune Stock Cools Off After Big Rally On Successful Eczema Trial (Benzinga)
Feb-11-26 07:53AM	Evommunes stock rallies 70% on Phase IIa eczema data (Clinical Trials Arena)
04:33AM	Evommune rockets on eczema data; AstraZeneca advances GLP-1 pill (BioPharma Dive)
Feb-10-26 04:07PM	Has Dupixent Met Its Match? Rivals Nektar, Evommune Catapult On Eczema Results. (Investor's Business Daily) +70.87%
12:29PM	Loading…
12:29PM	Evommune's Stock Surges On Strong Results For New Eczema Drug (Benzinga)
09:12AM	Evommune Nearly Doubles - Has Dupixent Met Its Match In Eczema? (Investor's Business Daily)
07:30AM	Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis (Business Wire)
Jan-19-26 11:28AM	High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026 (MarketBeat)
Dec-11-25 04:05PM	Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update (Business Wire) -8.53%
Dec-01-25 09:46AM	Carvana initiated, Zscaler downgraded: Wall Street's top analyst calls (The Fly)
Nov-06-25 03:39PM	What Shutdown? The IPO Window Is Still Open for Some Companies (Barrons.com)
08:55AM	NYSE Content Advisory: Pre-Market Update + Evommune & Aeromexico Begin Trading (PR Newswire)
Nov-05-25 07:45PM	Evommune Announces Pricing of its Initial Public Offering (PR Newswire)

Evommune, Inc. is a clinical-stage biotechnology company. It engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pena, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Palo Alto, CA.

FounderMr. Luis C. Pena

M.B.A.Mr. Kyle Carver CPA

Chief Business & Legal OfficerMr. Gregory S. Moss Esq.

Co-FounderDr. Eugene Andrew Bauer M.D.

Chief Scientific OfficerDr. Jeegar Patel Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GREGORY MOSS	Officer	May 28 '26	Proposed Sale	23.34	14,223	331,965		May 28 04:35 PM
KYLE CARVER	Officer	May 28 '26	Proposed Sale	23.34	25,675	599,254		May 28 04:35 PM
Hopfner Robert Lorne	Director	Dec 19 '25	Buy	17.35	1,000	17,350	4,026	Dec 22 07:07 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

EVMN

Evommune Inc

Upgrade your Finviz experience